

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FII	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/786,024 07/05/2001		Long Yu	A34054 PCTUSA	3983	
21003	7590	11/16/2001			
BAKER &		171	EXAMINER		
30 ROCKER NEW YORK				FRONDA, CHRISTIAN L	
				ART UNIT	PAPER NUMBER
				1652	
			DATE MAIL ED: 11/16/2001		

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/786,024 Applicant(s)

Examiner

Art Unit

Yu et al.



		Christian L. Fronda	1652				
	The MAILING DATE of this communication appears	on the cover sheet with the corres	p ndence addre	ess			
A SH	or Reply ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE1 MONTH	I(S) FROM				
- Exter aft - If the	isions of time may be available under the provisions of 37 Cerr SIX (6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) days considered timely.	cation.	, , ,	·			
co - Failur - Any ı	period for reply is specified above, the maximum statutory mmunication. The to reply within the set or extended period for reply will, be reply received by the Office later than three months after the rned patent term adjustment. See 37 CFR 1.704(b).	y statute, cause the application to bed	ome ABANDONE	D (35 U.S.C. § 133).			
Status							
1) 📙	Responsive to communication(s) filed on	-	1000101	· · ·			
2a) 🗌	This action is FINAL . 2b) 💢 This ac	tion is non-final.					
3) 🗌	Since this application is in condition for allowance closed in accordance with the practice under $Ex\ partial$			e merits is			
-	tion of Claims						
4) 💢	Claim(s) <u>1-14</u>	is/are	e pending in th	e application.			
2	a) Of the above, claim(s)	is/ar	e withdrawn fi	rom consideration.			
5) 🗌	Claim(s)		is/are allowed				
6) 🗆	Claim(s)		is/are rejected	,			
7) 🗆	Claim(s)		is/are objected	I to.			
8) 💢	Claims <u>1-14</u>	are subject to restric	ction and/or ele	ection requirement.			
Applica	tion Papers						
9) 🗆	The specification is objected to by the Examiner.						
10) 🗆	The drawing(s) filed on is/ard	e objected to by the Examiner.					
11)	The proposed drawing correction filed on is: a) approved b) disapproved.						
12)	The oath or declaration is objected to by the Exam	niner.					
Priority	under 35 U.S.C. § 119						
13) 🗌	Acknowledgement is made of a claim for foreign p	priority under 35 U.S.C. § 119(a)	-(d).				
a) 🗆	☐ All b)☐ Some* c)☐ None of:						
	1. Certified copies of the priority documents ha	ve been received.					
	2. U Certified copies of the priority documents ha						
	 Copies of the certified copies of the priority of application from the International Burges the attached detailed Office action for a list of the action for a	eau (PCT Rule 17.2(a)).	this National (Stage			
14)	Acknowledgement is made of a claim for domestic		(e).				
Attachm							
15} 💢 N	otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper	No(s).				
	ptice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application	(PTO-152)				
17] 📙 In	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:					

Application/Control Number: 09/786,024 Page 2

Art Unit: 1652

DETAILED ACTION

Election/Restriction

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

- I. Claims 1-3 and 6-11, drawn to an isolated DNA molecule, vector, a host cell, and method for producing a human lysozyme.
- II. Claims 4 and 5, drawn to a human lysozyme.
- III. Claim 12, drawn to an antibody.
- IV. Claim 13, drawn to an antisense DNA molecule.
- V. Claim 14, drawn to a DNA probe.
- 2. The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of the inventions listed as Groups I-VIII is a human lysozyme comprising a fragment of SEQ ID NO: 4. However, de Baetselier et al. (Accession AAR05721) teach a human lysozyme comprising a fragment of SEQ ID NO: 4 (See Alignment No. 1).

Since Applicants have not contributed a special technical feature over the prior art, Groups I-V do not have a single general inventive concept and therefore lack unity of invention.

- 3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any

Art Unit: 1652

amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L. Fronda whose telephone number is (703)305-1252. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703)308-3804. The fax phone number for this Group is (703)308-0294. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703)308-0196.

CLF

PONNATHAPUACHUMMURTHY SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600